1.5-Year Posttreatment Follow-Up of Radium-223 Dichloride (Ra-223) Safety in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases from Alsympca: Characterization of Hematologic Safety Profiles

null null Aim: In ALSYMPCA, the first-in-class alpha-emitter Ra-223 had a highly favorable safety profile and was well tolerated (Parker et al. NEJM 2013). Safety monitoring of Ra-223 is essential for a complete safety profile. Reported here are safety results of a post hoc analysis from an interim review of ∼1.5 years after the last pt's last injection. null Methods: Pts were to enter designated follow-up starting 4 weeks after their last...